FindTrial
Sign In

Relationship between intraoperative use of remifentanil and survival in patients undergoing laryngeal cancer surgery: a retrospective study

Relationship between intraoperative use of remifentanil and survival in patients undergoing laryngeal cancer surgery: a retrospective study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200066762
Enrollment
Unknown
Registered
2022-12-16
Start date
2023-01-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

laryngeal cancer surgery

Interventions

Less than 0.01mg/kg remifentanil:none
Greater than 0.01mg/kg remifentanil:none

Sponsors

The First Affiliated Hospital of Anhui Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) The pathologically confirmed laryngeal squamous cell carcinoma underwent surgical treatment; (2) there was no history of other malignant tumors; (3) there was no history of anti-tumor treatment before surgery; complete clinicopathological data and follow-up data were available.

Exclusion criteria

Exclusion criteria: (1) Lack of complete clinicopathological data and follow-up data. (2) The patient lost follow-up.

Design outcomes

Primary

MeasureTime frame
Survival of patients after surgery;—

Countries

China

Contacts

Public ContactKeyu Fan

First Affiliated Hospital of Anhui Medical University

215535169@qq.com17398381638

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026